Clinical trial · Interventional
The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Acute myeloid leukemia (AML) is the main type of leukemia, accounting for about 60% of all leukemia, with complex pathogenesis and great clinical heterogeneity. Effective targets for AML need to be further developed. We performed next-generation sequencing analysis of the TCR sequence of an AML patient to find the patient's specific TCR clone for leukemia. The rearranged TCR gene stimulated by leukemia antigens was transduced into the patient's own T cells, and the TCR gene-modified T cells (TCR-T) that could specifically recognize leukemia antigens and kill leukemia cells were constructed. Enhancing the specificity and killing activity of T cells can truly achieve individualized treatment for patients. In addition, through TCR sequencing, the TCR sequence database of leukemia patients can be constructed to find the common specific TCR clones for AML among different patients, which can realize the precise treatment of AML.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TCR-T Cells Injection | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- AML patients group
- description
- To construct TCR sequence database of acute myeloid leukemia patients, and then to verify the effect and mechanism of immunotherapy in vitro and in mice，then TCR gene-modified T cells were infused back into the patients
- interventionNames
- Biological: TCR-T Cells Injection
Primary outcomes (1)
- measure
- Decreased AML percentage in blood
- timeFrame
- From date of initial treatment to the 20 days after TCR-T Cells infusion
- description
- TCR-T Cells were infused back into the patients then the decreased percentage of AML tumor cells in blood after infusion was measured
Secondary outcomes (1)
- measure
- Decreased AML percentage in cerebrospinal fluid
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18-65 (≥ 18 years old, ≤ 65 years old) 2. gender is not limited 3. Acute myeloid leukemia patients 4. CR(remission phase, white blood cell count \> 2×10\^9/L after blood picture recovery) 5. After 3-4 courses of chemotherapy (the number of courses is not absolute) 6. Before the next chemotherapy Exclusion Criteria: 1. Transformed acute myeloid leukemia 2. Secondary acute myeloid leukemia 3. Post-transplantation acute myeloid leukemia 4. AML-M3 5. white blood cell count \<2×10\^9/L 6. More than 8 courses of chemotherapy 7. Combined with other immune-related diseases 8. Pregnancy
References
Publications (0)
Data not yet available